Fifteen Years of Annual Mass Treatment of Onchocerciasis with Ivermectin Have Not Interrupted Transmission in the West Region of Cameroon
Table 4
Comparing nodule prevalence among adults at baseline (1996) and followup in 2005, 2006, and 2011, three months, six months, and eleven months, respectively, after mass treatment, in West Region, Cameroon.
District
Community
Baseline, 1996 ()
Followup, 2005 ()
Followup, 2006 ()
Followup, 2011 ()
No. examined
No. positive
% nodule positive
No. examined
No. positive
% nodule positive
No. examined
No. positive
% nodule positive
No. examined
No. positive
% nodule positive
Bafang
Bakassa
27
16
59.3
139
11.0
7.9*
97
11
11.3
251
21
8.4
Bakonti
27
11
40.7
98
5.0
5.1*
75
5
6.7
338
36
10.7
Fondjanti
27
19
70.4
125
29
23.2
Bakambe
27
19
70.4
105
11.0
10.5*
91
13
14.3
125
29
23.2
Baham
Bapi
29
15
51.7
ND
ND
ND
ND
ND
ND
189
15
7.9
Bandja
Babouantou (Batoula)
26
16
61.5
61
5.0
8.2*
76
18
23.7**
84
12
14.3
Bangangté
Batchingou
29
22
75.9
101
16.0
15.8*
80
23
28.8**
247
29
11.7***
Ndjipta III (Fop-Tchui)
29
23
79.3
78
5.0
6.4*
57
8
14.0**
92
9
9.8
Foumbot
Fossang-chefferie
28
24
85.7
71
7.0
9.9*
72
18
25.0**
150
26
17.3***
Njone
29
26
89.7
34
9.0
26.5*
122
37
30.3
167
31
18.6***
Kekem
Mbafam
24
17
70.8
93
5.0
5.4*
112
12
10.7**
163
27
16.6
Penka-Michel
Bakassa
30
12
40.0
ND
ND
ND
ND
ND
ND
195
15
7.7
Foumban
Folap
ND
ND
ND
ND
ND
ND
ND
ND
ND
265
4
1.5
Kouoptamo
Njisseng
ND
ND
ND
ND
ND
ND
ND
ND
ND
168
6
3.6
Malantouen
Matoupou
ND
ND
ND
ND
ND
ND
ND
ND
ND
170
9
5.3
Massangam
Makouopsap
ND
ND
ND
ND
ND
ND
ND
ND
ND
99
43
43.4
332
220
66.3
780
74
9.5
*
782
145
18.5
**
2828
341
12.1
***
ND: not done.
*Significant ( < 0.05)—followup 2005 compared with the baseline.
**Significant ( < 0.05)—followup 2006 compared with 2005 followup.
***Significant ( < 0.05)—followup 2011 compared with 2006 followup.
